mrk and mrna big gain with other biostocks, what they are in complete list?

 The major sector-wide biotech rally was triggered by the historic Phase 3 clinical trial success of Moderna (MRNA) and Merck (MRK) for their personalized mRNA cancer vaccine, Intismeran. While Moderna surged up to 177% intraday and Merck added over 12%, the breakthrough sparked an industry-wide "shot in the arm", sending competitor vaccine developers, gene-editing companies, and AI-biotechs soaring. [1, 2, 3, 4]

The complete list of biotech and pharmaceutical stocks that rallied alongside MRK and MRNA, categorized by their sub-sectors, includes:

💉 Direct Vaccine Competitors & Platform Peers

These companies use similar mRNA or viral vector technology and jumped on the validation of the cancer-vaccine concept: [1, 2]

BioNTech (BNTX): Surged ~20%. They are Moderna's primary mRNA rival and are also developing personalized cancer vaccines for colorectal and pancreatic cancers.
Novavax (NVAX): Gained sharply following the announcement.
Transgene (TGNOF / French listing): Rallied 15% on the news. They develop personalized cancer vaccines using viral vectors.
Roche (RHHBY): Rose 1.8%. Roche owns Genentech, which is BioNTech’s primary partner on personalized oncology vaccines. [1, 2]

🧬 Advanced Gene Editing Companies

Companies specializing in curative genomic therapies experienced massive sympathy gains as investors rotated back into high-growth biotech platforms: [1, 2]

Prime Medicine (PRME)
Intellia Therapeutics (NTLA)
CRISPR Therapeutics (CRSP)
Editas Medicine (EDIT)
Beam Therapeutics (BEAM) [1]

🤖 AI-Driven Biotechnology Companies

AI-focused discovery platforms jumped due to a combination of general sector enthusiasm and simultaneous independent AI tech catalyst announcements: [1]

Absci Corporation (ABSI)
Recursion Pharmaceuticals (RXRX)
Twist Bioscience (TWST) [1, 2]

📈 Broader Oncology & Immunotherapy Ralliers

Eli Lilly (LLY): Gained 5.3% to secure its status as the world's most valuable pharma company, pushing its valuation past $1.1 trillion. [1]
BriaCell Therapeutics (BCT): Surged over 12% due to renewed investor interest in its advanced metastatic breast cancer immunotherapy pipeline. [1]
Repligen (RGEN): Experienced target upgrades and price appreciation due to its potential exposure to Moderna's manufacturing and clinical pipeline. [1]

---

📊 Major Biotech ETFs to Watch

If you prefer broad exposure over picking single stocks, the entire sector's lifting tide was clearly visible across major index funds, which had historic days: [1]

iShares Genomics Immunology and Healthcare ETF (IDNA): Jumped 13% for its best day on record.
ARK Genomic Revolution ETF (ARKG): Surged 10%.
SPDR S&P Biotech ETF (XBI): Gained 6%. [1, 2]

⚠️ Speculation Warning: Biotechnology stocks carry extreme volatility. Following massive single-day surges like this one, it is common to see short-term pullbacks (Moderna fell back roughly 16–20% the following morning as investors locked in profits). A sudden rally can lead to a complete capital loss if a company's next trial phase fails or faces regulatory hurdles. Diversifying through sector ETFs or leaning on foundational mega-caps like Merck is a safer way to participate in the trend. [1, 2, 3, 4, 5]